サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1483023

医薬品原薬 (API) の世界市場：製品タイプ (新規・ジェネリック)・製造業者 (キャプティブ・マーチャント)・合成 (合成・バイオテクノロジー)・製品 (mAb・ホルモン・サイトカイン)・医薬品 (OTC薬・処方薬)・用途 (糖尿病・癌・CVD) 別の予測 (～2029年)

Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (captive, merchant), Synthesis (Synthetic, Biotech), Products (mAb, Hormones, Cytokines), Drug (OTC, Rx), Application (Diabetes, oncology, CVD) - Global Forecast to 2029
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 535 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.13円
医薬品原薬 (API) の世界市場：製品タイプ (新規・ジェネリック)・製造業者 (キャプティブ・マーチャント)・合成 (合成・バイオテクノロジー)・製品 (mAb・ホルモン・サイトカイン)・医薬品 (OTC薬・処方薬)・用途 (糖尿病・癌・CVD) 別の予測 (～2029年)
出版日: 2024年05月17日
発行: MarketsandMarkets
ページ情報: 英文 535 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品原薬 (API) の市場規模は、2024年の1,635億米ドルから、予測期間中は7.8%のCAGRで推移し、2029年には2,383億米ドルの規模に成長すると予測されています。

同市場の成長は、新規バイオ医薬品開発のためのR&D活動が活発化していることに起因しています。バイオ医薬品は、生物を利用して製造されます。ヒトの体内に存在する天然の生物学的化合物に類似しているため、高い有効性と副作用の少なさを実現できるとして人気を集めています。バイオ医薬品の分野における継続的な研究により、新規製品の開発や既存の治療モデルの進歩がもたらされました。現在、遺伝子治療 (再生医療) や細胞治療 (癌治療) といった新しいコンセプトが洗練されつつあります。このため、バイオ医薬品はAPI市場における巨大かつ魅力的な機会の領域となっています。バイオ医薬品は現在、医薬品業界で最も急成長している分野であり、今後10年間で2桁の成長率を記録すると予想されています。

調査範囲
調査対象年 2022-2029年
基準年 2023年
予測期間 2024-2029年
単位 金額 (米ドル)
セグメント タイプ・合成・薬剤タイプ・効力・治療用途・エンドユーザー
対象地域 北米・欧州・アジア太平洋・ラテンアメリカ・中東&アフリカ

エンドユーザー別では、製薬・バイオ産業の部門が予測期間中に最大のシェアを占める：

製薬・バイオ産業は2023年のAPIの重要なエンドユーザーグループです。製薬会社は、錠剤、カプセル剤、注射剤などの最終製剤を製造するためにAPIを調達します。バイオテクノロジー企業は、生物由来のバイオ医薬品の開発に重点を置いています。製薬企業やバイオテクノロジー企業とAPIプロバイダーとの協力関係の拡大も、市場成長を支える要因の一つです。

欧州がAPI市場で2番目に大きな地域に：

API市場では、北米に次いで欧州が第2位の市場を占めています。欧州市場は、慢性疾患の罹患率の増加など人口動態の変化に牽引され、近年著しい成長を遂げています。これは、同地域における老齢人口の増加に起因しています。欧州委員会の発表によると、2025年までに欧州人口の20％以上が65歳以上になると予想され、80歳以上の高齢者も急増することから、ヘルスケア施設や疾病診断サービスに対する需要が大きく伸びることが予想されます。このことは、新薬発見のための医薬品・バイオ医薬品の臨床試験活動を促進し、APIなどの関連市場の成長に直接貢献することとなります。

当レポートでは、世界の医薬品原薬 (API) の市場を調査し、市場概要、市場影響因子および市場機会の分析、技術・特許の動向、法規制環境、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 動向
  • 技術分析
  • サプライチェーン分析
  • バリューチェーン分析
  • 価格分析
  • エコシステム分析
  • 特許分析
  • 主な会議とイベント
  • 規制状況
  • ポーターのファイブフォース分析
  • 主なステークホルダーと購入基準
  • 投資と資金調達のシナリオ
  • 取引データ

第6章 医薬品原薬 (API) 市場：タイプ別

  • API市場：タイプ別 (キャプティブおよびマーチャント)
  • 新規API
  • ジェネリックAPI

第7章 医薬品原薬 (API) 市場：合成別

  • API市場：合成別 (キャプティブおよびマーチャント)
  • 合成API
  • バイオテクノロジーAPI
    • タイプ別
    • 製品別
    • 発現システム別

第8章 医薬品原薬 (API) 市場：医薬品タイプ別

  • API市場：医薬品タイプ別 (キャプティブおよびマーチャント)
  • 処方薬
  • OTC薬

第9章 医薬品原薬 (API) 市場：効力別

  • API市場：効力別 (キャプティブおよびマーチャント)
  • 従来のAPI
  • 強力なAPI

第10章 医薬品原薬 (API) 市場：治療用途別

  • API市場：治療用途別 (キャプティブおよびマーチャント)
  • 伝染病
  • 腫瘍
  • 糖尿病
  • 心血管疾患
  • 呼吸器疾患
  • 疼痛管理
  • その他

第11章 医薬品原薬 (API) 市場：エンドユーザー別

  • API市場：エンドユーザー別 (キャプティブおよびマーチャント)
  • 製薬・バイオテクノロジー業界
  • CRO
  • CMO
  • その他

第12章 医薬品原薬 (API) 市場：地域別

  • API市場：地域別 (キャプティブおよびマーチャント)
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東
  • アフリカ

第13章 競合情勢

  • 主要企業戦略/有力企業
  • 収益分析
  • 市場シェア分析
  • 企業評価マトリックス：主要企業
  • 企業評価マトリックス：スタートアップ/中小企業
  • 評価と財務指標
  • ブランド/製品比較
  • 競合シナリオ

第14章 企業プロファイル

  • 主要企業
    • PFIZER INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • GSK PLC
    • SANOFI
    • VIATRIS INC.
    • DIVI'S LABORATORIES LIMITED
    • SANDOZ GROUP AG
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • SK INC.
    • ELI LILLY AND COMPANY
    • MERCK KGAA
    • ABBVIE INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • ASTRAZENECA
    • DR. REDDY'S LABORATORIES LTD.
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • CIPLA
    • AUROBINDO PHARMA
    • EVONIK INDUSTRIES AG
    • HIKMA PHARMACEUTICALS PLC
    • BASF SE
    • ALEMBIC PHARMACEUTICALS LIMITED
  • その他の企業
    • ABURAIHAN PHARMACEUTICAL COMPANY
    • CURIA GLOBAL, INC.
    • CAMBREX CORPORATION
    • API PHARMA TECH
    • SREEPATHI PHARMACEUTICALS LIMITED
    • SHILPA MEDICARE LIMITED
    • NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.
    • HOVIONE
    • CHEMCON GMBH
    • PHARCO

第15章 付録

目次
Product Code: PH 1262

The global active pharmaceutical ingredients market is projected to reach USD 238.3 billion by 2029 from USD 163.5 billion in 2024, at a CAGR of 7.8% during the forecast period of 2024 to 2029. The growth of this market can be attributed to the increasing research and development activities for the development of novel biopharmaceuticals. Biopharmaceuticals are manufactured by using living biological systems. They have become popular as they are similar to natural biological compounds found in the human body, thus offering higher efficacy and fewer side effects. Continued research in the field of biologics has resulted in the development of novel products and advancements in existing treatment models. Currently, novel concepts such as gene therapy (offering regenerative medicine) and cell therapy (for cancer treatment) are being refined. This has made biopharmaceuticals a huge and attractive opportunity area in the active pharmaceutical ingredients market. Biopharmaceuticals are currently the fastest-growing segment of the pharmaceutical industry, expected to register a double-digit growth rate in the coming decade. Their efficacy and safety, combined with their ability to address previously untreatable conditions, allow pharmaceutical companies to command high prices for these innovative drugs. Currently, a majority of blockbuster drugs are biopharmaceuticals. According to PharmaVoice report in 2023, pharmaceutical's biggest blockbusters included Merck & Co.'s Keytruda, Pfizer and BioNTech's COVID-19 vaccine Comirnaty, and AbbVie's powerhouse Humira.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsType, Synthesis, Type of Drug, Potency, Therapeutic Applications, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The pharmaceutical & biotechnology industry segment accounted for the largest share by end user during the forecast period."

In 2023, The pharmaceutical and biotechnology industry is a significant end user group of Active Pharmaceutical Ingredients (APIs) for drug development and manufacturing. Pharmaceutical companies utilize APIs as the primary component in their drug formulations. These compounds provide the therapeutic effects of the medication. They procure APIs to produce finished dosage forms, such as tablets, capsules, or injectables. Biotechnology firms focus on developing biologic drugs, which are derived from living organisms. These drugs typically involve complex molecules, proteins, or antibodies. Growing collaboration by pharmaceutical and biotechnology companies with API providers is one of the factors supporting market growth. For instance, in December 2022, Eli Lilly and Company and EVA Pharma collaborated through which Eli Lilly committed to supply its active pharmaceutical ingredient (API) for insulin at a significantly reduced price to EVA Pharma. Additionally, as the need for the development of novel treatments is growing, the pharmaceutical and biotechnology industry is focused on continuously innovating in this field. This is further expected to support market growth.

"Europe: The second largest region in the active pharmaceutical ingredients market."

Europe accounted for the second-largest market for active pharmaceutical ingredients market after North America. The European active pharmaceutical ingredients market has witnessed significant growth in recent years, driven by demographic changes, such as the growing incidence of chronic diseases. This is attributed to the rising geriatric population in the region. As per the European Commission, by 2025, more than 20% of Europeans are expected to be 65 years and above, with a rapid increase in the number of people aged 80 years and above, indicating strong demand growth for healthcare facilities and disease diagnostics services. This will drive pharmaceutical and biopharmaceutical clinical trial activity for novel drug discoveries and directly contribute to the growth of associated markets, such as active pharmaceutical ingredients.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, CXOs and Directors-level - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America- 10%, and Middle East and Africa- 5%

List of Companies Profiled in the Report:

  • Pfizer Inc. (US)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GSK PLC (UK)
  • Sanofi (France)
  • Viatris Inc. (US)
  • Divi's Laboratories Limited (India)
  • Sandoz Group AG (Switzerland)
  • Boehringer Ingelheim International GmBH (US)
  • SK Inc. (US)
  • Eli Lilly and Company (US)
  • Merck KGaA (US)
  • AbbVie Inc. (US)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AstraZeneca (UK)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Cipla (India)
  • Aurobindo Pharma (India)
  • Evonik Industries AG (Germany)
  • Hikma Pharmaceuticals PLC (UK)
  • BASF SE (Germany)
  • Alembic Pharmaceuticals Limited (India)
  • Aburaihan Pharmaceutical Company (Iran)
  • Curia Global, Inc. (US)
  • Cambrex Corporation (US)
  • API Pharma Tech (US)
  • Sreepathi Pharmaceuticals Limited (India)
  • Shilpa Medicare Limited (India)
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China)
  • Hovione (Portugal)
  • ChemCon GmbH (Germany)
  • Pharco (Egypt)

Research Coverage:

This report provides a detailed picture of the active pharmaceutical ingredients market. It aims at estimating the size and future growth potential of the market across different segments such as the type, synthesis, type of drug, potency, therapeutic applications, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies. Market evaluation framework, market share analysis, revenue analysis, company evaluation matrix for the top 32 companies, SME/start-up evaluation matrix, company footprint, competitive benchmarking of SMEs/start-ups, competitive scenario, and valuation & financial metrics of key vendors have been updated in the competitive landscape chapter of the report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges

The report provides insights on the following pointers:

  • Analysis of key drivers (Production capacity expansion in pharmaceutical and biopharmaceutical companies, Growing adoption of generic drugs, Increasing uptake of biopharmaceuticals and Technological advancements in API manufacturing), restraints (Complications during API manufacturing, Low profit margins and high manufacturing costs), opportunities (Increased use of highly potent active pharmaceutical ingredients, and Potential growth opportunities in emerging economies), and challenges (Rising penetration of counterfeit drugs and Stringent regulatory requirements for API manufacturing).
  • Product Development/Innovation: Detailed insights on newly launched product and technological assessment of the active pharmaceutical ingredients market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the active pharmaceutical ingredients market
  • Competitive Assessment: In-depth assessment of market shares, technology analysis, investment and funding scenario, company footprint analysis, growth strategies and product offerings of leading players like Pfizer Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), GSK PLC (UK), Sanofi (France), Viatris Inc. (US), Divi's Laboratories Limited (India), Sandoz Group AG (Switzerland), Boehringer Ingelheim International GmBH (US), SK Inc. (US), Eli Lilly and Company (US), Merck KGaA (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Dr. Reddy's Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals PLC (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Aburaihan Pharmaceutical Company (Iran), Curia Global, Inc. (US), Cambrex Corporation (US), API Pharma Tech (US), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), Hovione (Portugal), ChemCon GmbH (Germany), and Pharco (Egypt).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 INCLUSIONS AND EXCLUSIONS
  • 1.4 STUDY SCOPE
    • 1.4.1 MARKET SEGMENTATION
    • FIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SEGMENTS COVERED
    • 1.4.2 REGIONAL SEGMENTATION
    • FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONS COVERED
    • 1.4.3 YEARS CONSIDERED
    • 1.4.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 RESEARCH LIMITATIONS
  • 1.7 SUMMARY OF CHANGES
    • 1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 3 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries
    • FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 ACTIVE PHARMACEUTICAL INGREDIENT MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
    • 2.2.1 GLOBAL MARKET ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
    • FIGURE 7 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS (2023)
    • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
    • FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
    • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION
    • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.3 MARKET GROWTH RATE PROJECTION
    • FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: CAGR PROJECTIONS
    • 2.3.1 IMPACT ANALYSIS OF DEMAND-SIDE AND SUPPLY-SIDE FACTORS
    • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 IMPACT OF ECONOMIC RECESSION ON ACTIVE PHARMACEUTICAL INGREDIENT MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 12 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
    • FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2024 VS. 2029 (USD BILLION)
    • FIGURE 14 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2024 VS. 2029 (USD BILLION)
    • FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2024 VS. 2029 (USD BILLION)
    • FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2023
    • FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
    • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENT MARKET

4 PREMIUM INSIGHTS

  • 4.1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET OVERVIEW
    • FIGURE 19 INCREASING R&D FUNDING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET
  • 4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE AND COUNTRY, 2023
    • FIGURE 20 US AND INNOVATIVE APIS COMMANDED LARGEST MARKET SHARE IN 2023
  • 4.3 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2024 VS. 2029
    • FIGURE 21 SYNTHETIC APIS TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.4 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2023
    • FIGURE 22 TRADITIONAL APIS POSSESSED LARGEST MARKET SHARE IN 2023
  • 4.5 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 24 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Production capacity expansion in pharmaceutical & biopharmaceutical companies
      • 5.2.1.2 Growing adoption of generic drugs
    • FIGURE 25 TOTAL SAVINGS FROM GENERIC DRUG USAGE IN US, 2013-2022 (USD BILLION)
    • TABLE 3 INDICATIVE LIST OF DRUGS GOING OFF-PATENT IN 2024
      • 5.2.1.3 Increasing uptake of biopharmaceuticals
    • FIGURE 26 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028 (USD BILLION)
      • 5.2.1.4 Technological advancements in API manufacturing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complications during API manufacturing
      • 5.2.2.2 Low profit margin and high manufacturing cost
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased use of highly potent APIs
      • 5.2.3.2 Potential growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Rising penetration of counterfeit drugs
      • 5.2.4.2 Stringent regulatory requirements for API manufacturing
    • 5.2.5 TRENDS
      • 5.2.5.1 Increased outsourcing to contract manufacturing organizations
      • 5.2.5.2 Shift towards continuous processing
  • 5.3 TECHNOLOGY ANALYSIS
    • 5.3.1 KEY TECHNOLOGIES
      • 5.3.1.1 Continuous manufacturing
      • 5.3.1.2 Advanced analytical technique
      • 5.3.1.3 Biocatalysis
    • 5.3.2 COMPLIMENTARY TECHNOLOGIES
      • 5.3.2.1 Data analytics and digitalization
      • 5.3.2.2 Personalized medicine and custom synthesis
      • 5.3.2.3 Supercritical fluid technology
    • 5.3.3 ADJACENT TECHNOLOGIES
      • 5.3.3.1 Supply chain visibility and blockchain
      • 5.3.3.2 3D printing
      • 5.3.3.3 Nanotechnology
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 27 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SUPPLY CHAIN ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 28 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: VALUE CHAIN ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER
    • TABLE 4 AVERAGE SELLING PRICE OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 29 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ECOSYSTEM ANALYSIS
    • 5.7.1 RAW MATERIAL SUPPLIERS
    • TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF RAW MATERIAL SUPPLIERS IN ECOSYSTEM
    • 5.7.2 INGREDIENT VENDORS
    • TABLE 6 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF INGREDIENT VENDORS IN ECOSYSTEM
    • 5.7.3 END USERS
    • TABLE 7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF END USERS IN ECOSYSTEM
    • 5.7.4 REGULATORY BODIES
    • TABLE 8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF REGULATORY BODIES IN ECOSYSTEM
  • 5.8 PATENT ANALYSIS
    • 5.8.1 METHODOLOGY
    • 5.8.2 NUMBER OF PATENTS FILED
    • TABLE 9 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: NUMBER OF PATENTS FILED, 2014-2023
    • 5.8.3 INNOVATION AND PATENT APPLICATIONS
    • FIGURE 30 TOTAL NUMBER OF PATENTS GRANTED FOR ACTIVE PHARMACEUTICAL INGREDIENTS, 2014-2023
    • 5.8.4 TOP APPLICANTS
    • FIGURE 31 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2023
    • TABLE 10 TOP 20 PATENT OWNERS IN ACTIVE PHARMACEUTICAL INGREDIENT MARKET, 2014-2023
  • 5.9 KEY CONFERENCES AND EVENTS, 2024-2025
    • TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
  • 5.10 REGULATORY LANDSCAPE
    • 5.10.1 REGULATORY SCENARIO
      • 5.10.1.1 North America
        • 5.10.1.1.1 US
        • 5.10.1.1.2 Canada
      • 5.10.1.2 Europe
        • 5.10.1.2.1 Germany
        • 5.10.1.2.2 UK
      • 5.10.1.3 Asia Pacific
        • 5.10.1.3.1 Japan
      • 5.10.1.4 Latin America
        • 5.10.1.4.1 Brazil
      • 5.10.1.5 Middle East & Africa
        • 5.10.1.5.1 Saudi Arabia
    • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 17 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS
    • 5.12.2 KEY BUYING CRITERIA
    • FIGURE 33 KEY BUYING CRITERIA FOR END USERS
    • TABLE 18 KEY BUYING CRITERIA, BY END USER
  • 5.13 INVESTMENT AND FUNDING SCENARIO
  • 5.14 TRADE DATA
    • 5.14.1 IMPORT DATA FOR ANTIBIOTICS (HS CODE: 2941)
    • TABLE 19 IMPORTERS FOR ANTIBIOTICS (HS CODE-2941)
    • 5.14.2 EXPORT DATA FOR ANTIBIOTICS (HS CODE: 2941)
    • TABLE 20 EXPORTERS FOR ANTIBIOTICS (HS CODE-2941)
    • 5.14.3 IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS (HS CODE: 2934)
    • TABLE 21 IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) (HS CODE-2934)
    • 5.14.4 EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS (HS CODE: 2934)
    • TABLE 22 EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) (HS CODE-2934)
    • 5.14.5 IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE: 2937)
    • TABLE 23 IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDES CHAIN MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE-2937)
    • 5.14.6 EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE: 2937)
    • TABLE 24 EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDES CHAIN MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE-2937)

6 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 25 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • 6.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT)
    • TABLE 26 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 27 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
  • 6.3 INNOVATIVE APIS
    • 6.3.1 INCREASING NUMBER OF REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO BOOST MARKET GROWTH
    • TABLE 28 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 29 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 30 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 31 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 32 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 33 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 34 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
  • 6.4 GENERIC APIS
    • 6.4.1 INCREASED FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET GROWTH
    • TABLE 35 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 36 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 37 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 38 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 39 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 40 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 41 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)

7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS

  • 7.1 INTRODUCTION
    • TABLE 42 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 (USD BILLION)
  • 7.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS (CAPTIVE AND MERCHANT)
    • TABLE 43 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 44 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 (USD BILLION)
  • 7.3 SYNTHETIC APIS
    • TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 46 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 47 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 48 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 49 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 50 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 51 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • 7.3.1 SYNTHETIC APIS MARKET, BY TYPE
    • TABLE 52 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
      • 7.3.1.1 Innovative synthetic APIs
        • 7.3.1.1.1 Innovative synthetic APIs to command larger market share during forecast period
    • TABLE 53 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 54 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 55 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 56 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 57 LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 58 MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 59 GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.3.1.2 Generic synthetic APIs
        • 7.3.1.2.1 Cost effectiveness and increased government support to fuel market growth
    • TABLE 60 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 61 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 62 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 63 ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 64 LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 65 MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 66 GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • 7.4 BIOTECH APIS
    • TABLE 67 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 68 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 69 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 70 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 71 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 72 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 73 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • 7.4.1 BIOTECH APIS MARKET, BY TYPE
    • TABLE 74 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
      • 7.4.1.1 Innovative biotech APIs
        • 7.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive segment
    • TABLE 75 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 76 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 77 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 78 ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 79 LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 80 MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 81 GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.1.2 Generic biotech APIs
        • 7.4.1.2.1 High demand for biosimilars to propel segment growth
    • TABLE 82 GENERIC BIOTECH APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 83 NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 84 EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 85 ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 86 LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 87 MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 88 GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • 7.4.2 BIOTECH APIS MARKET, BY PRODUCT
    • TABLE 89 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT 2022-2029 (USD BILLION)
      • 7.4.2.1 Monoclonal antibodies
        • 7.4.2.1.1 Growing applications of antibody-drug conjugates in cancer treatment to drive segment
    • TABLE 90 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 91 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 92 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 93 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 94 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 95 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 96 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.2.2 Hormones & growth factors
        • 7.4.2.2.1 Rising incidence of hormonal imbalance among geriatric and neonatal population to aid segment growth
    • TABLE 97 HORMONES & GROWTH FACTORS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 98 NORTH AMERICA: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 99 EUROPE: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 100 ASIA PACIFIC: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 101 LATIN AMERICA: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 102 MIDDLE EAST: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 103 GCC COUNTRIES: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.2.3 Fusion proteins
        • 7.4.2.3.1 Growing applications in biopharmaceuticals to augment segment growth
    • TABLE 104 FUSION PROTEINS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 105 NORTH AMERICA: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 106 EUROPE: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 107 ASIA PACIFIC: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 108 LATIN AMERICA: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 109 MIDDLE EAST: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 110 GCC COUNTRIES: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.2.4 Cytokines
        • 7.4.2.4.1 Effective use in regulating immune system, inflammation, and cell growth to augment segment growth
    • TABLE 111 CYTOKINES MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 112 NORTH AMERICA: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 113 EUROPE: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 114 ASIA PACIFIC: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 115 LATIN AMERICA: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 116 MIDDLE EAST: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 117 GCC COUNTRIES: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.2.5 Therapeutic enzymes
        • 7.4.2.5.1 Growing use in cancer and pain management therapies to drive segment
    • TABLE 118 THERAPEUTIC ENZYMES MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 119 NORTH AMERICA: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
  • 7.4.3
    • TABLE 120 EUROPE: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 121 ASIA PACIFIC: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 122 LATIN AMERICA: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 123 MIDDLE EAST: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 124 GCC COUNTRIES: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.3.1 Blood factors & anti-coagulants
        • 7.4.3.1.1 Rising incidence of hemophilia to drive market
    • TABLE 125 BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 126 NORTH AMERICA: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 127 EUROPE: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 128 ASIA PACIFIC: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 129 LATIN AMERICA: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 130 MIDDLE EAST: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 131 GCC COUNTRIES: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.3.2 Recombinant vaccines
        • 7.4.3.2.1 Increasing funding for vaccine development to boost segment growth
    • TABLE 132 RECOMBINANT VACCINES MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 137 MIDDLE EAST: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 138 GCC COUNTRIES: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • 7.4.4 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM
    • TABLE 139 PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
      • 7.4.4.1 Mammalian expression systems
        • 7.4.4.1.1 High expression level and easy scalability to propel segment growth
    • TABLE 140 MAMMALIAN EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 141 NORTH AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 142 EUROPE: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 143 ASIA PACIFIC: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 144 LATIN AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 145 MIDDLE EAST: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 146 GCC COUNTRIES: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.4.2 Microbial expression systems
        • 7.4.4.2.1 High expression levels of proteins at low costs to augment segment growth
    • TABLE 147 MICROBIAL EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 148 NORTH AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 149 EUROPE: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 150 ASIA PACIFIC: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 151 LATIN AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 152 MIDDLE EAST: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 153 GCC COUNTRIES: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.4.3 Yeast expression systems
        • 7.4.4.3.1 Availability of efficient protein secretion and simple purification process to boost demand
    • TABLE 154 YEAST EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 155 NORTH AMERICA: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 156 EUROPE: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 157 ASIA PACIFIC: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 158 LATIN AMERICA: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 159 MIDDLE EAST: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 160 GCC COUNTRIES: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.4.4 Insect expression systems
        • 7.4.4.4.1 Effective post-translational modifications to boost segment growth
    • TABLE 161 INSECT EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 162 NORTH AMERICA: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 163 EUROPE: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 164 ASIA PACIFIC: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 165 LATIN AMERICA: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 166 MIDDLE EAST: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 167 GCC COUNTRIES: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
      • 7.4.4.5 Other expression systems
    • TABLE 168 OTHER EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 169 NORTH AMERICA: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 170 EUROPE: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 171 ASIA PACIFIC: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 172 LATIN AMERICA: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 173 MIDDLE EAST: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 174 GCC COUNTRIES: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)

8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG

  • 8.1 INTRODUCTION
    • TABLE 175 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
  • 8.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)
    • TABLE 176 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 177 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
  • 8.3 PRESCRIPTION DRUGS
    • 8.3.1 INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT MARKET GROWTH
    • TABLE 178 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 179 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 180 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 181 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 182 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 183 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 184 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
  • 8.4 OVER-THE-COUNTER DRUGS
    • 8.4.1 RISING PROMOTION OF SELF-MEDICATION TO PROPEL MARKET GROWTH
    • TABLE 185 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 186 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 187 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 188 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 189 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 190 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 191 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)

9 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY

  • 9.1 INTRODUCTION
    • TABLE 192 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
  • 9.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (CAPTIVE AND MERCHANT)
    • TABLE 193 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 194 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
  • 9.3 TRADITIONAL APIS
    • 9.3.1 INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH
    • TABLE 195 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 196 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 197 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 198 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 199 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 200 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 201 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
  • 9.4 HIGHLY POTENT APIS
    • 9.4.1 RISING PREVALENCE OF CANCER AND GROWING APPLICATIONS IN ONCOLOGY TO AID MARKET GROWTH
    • TABLE 202 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 203 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 204 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 205 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 206 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 207 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 208 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)

10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 209 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
  • 10.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT)
    • TABLE 210 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 211 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
  • 10.3 COMMUNICABLE DISEASES
    • 10.3.1 COMMUNICABLE DISEASES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
    • TABLE 212 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 213 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 214 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 215 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 216 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 217 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 218 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • 10.4 ONCOLOGY
    • 10.4.1 INCREASING INCIDENCE OF CANCER AND RISING NUMBER OF FDA APPROVALS FOR ONCOLOGY DRUGS TO DRIVE MARKET
    • TABLE 219 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER
    • TABLE 220 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 221 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 222 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 223 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 224 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 225 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 226 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
  • 10.5 DIABETES
    • 10.5.1 LARGE GERIATRIC POPULATION AND HIGH OBESITY RATES TO SUPPORT MARKET GROWTH
    • TABLE 227 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 228 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 229 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 230 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 231 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 232 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 233 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
  • 10.6 CARDIOVASCULAR DISEASES
    • 10.6.1 INCREASING INVESTMENT IN ADVANCED CARDIOVASCULAR THERAPIES TO AID MARKET GROWTH
    • TABLE 234 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 235 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 236 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 237 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 238 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 239 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 240 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • 10.7 RESPIRATORY DISEASES
    • 10.7.1 INCREASING POLLUTION LEVELS AND GROWING NUMBER OF COPD CASES TO FUEL MARKET GROWTH
    • TABLE 241 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2022
    • TABLE 242 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 243 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 244 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 245 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 246 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 247 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 248 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
  • 10.8 PAIN MANAGEMENT
    • 10.8.1 INCREASING DEMAND FOR ADVANCED PAIN MEDICATIONS TO PROPEL MARKET GROWTH
    • TABLE 249 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 250 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 251 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 252 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 253 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 254 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 255 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
  • 10.9 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 256 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 257 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 258 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 259 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 260 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 261 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 262 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)

11 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER

  • 11.1 INTRODUCTION
    • TABLE 263 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 11.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (CAPTIVE AND MERCHANT)
    • TABLE 264 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 265 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 11.3 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
    • 11.3.1 INCREASING NUMBER OF COLLABORATIONS TO SUPPORT MARKET GROWTH
    • TABLE 266 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 267 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 268 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 269 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 270 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 271 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 272 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
  • 11.4 CONTRACT RESEARCH ORGANIZATIONS
    • 11.4.1 INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT MARKET GROWTH
    • TABLE 273 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 274 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 275 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 276 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 277 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 278 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 279 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • 11.5 CONTRACT MANUFACTURING ORGANIZATIONS
    • 11.5.1 INCREASED FOCUS ON BETTER QUALITY TO AID MARKET GROWTH
    • TABLE 280 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 281 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 282 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 283 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 284 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 285 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 286 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
  • 11.6 OTHER END USERS
    • TABLE 287 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD BILLION)
    • TABLE 288 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 289 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 290 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 291 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 292 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 293 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)

12 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION

  • 12.1 INTRODUCTION
    • TABLE 294 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2022-2029 (USD BILLION)
  • 12.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (CAPTIVE AND MERCHANT)
    • TABLE 295 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
    • TABLE 296 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2022-2029 (USD BILLION)
  • 12.3 NORTH AMERICA
    • 12.3.1 NORTH AMERICA: RECESSION IMPACT
    • FIGURE 34 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET SNAPSHOT
    • TABLE 297 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 298 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 299 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 300 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 301 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 302 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 303 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 304 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 305 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 306 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 307 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.3.2 US
      • 12.3.2.1 US to dominate North American active pharmaceutical ingredient market during study period
    • TABLE 308 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 309 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 310 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 311 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 312 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 313 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 314 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 315 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 316 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 317 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.3.3 CANADA
      • 12.3.3.1 Growing pharmaceutical manufacturing industry to support market growth
    • TABLE 318 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 319 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 320 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 321 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 322 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 323 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 324 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 325 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 326 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 327 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 12.4 EUROPE
    • 12.4.1 EUROPE: RECESSION IMPACT
    • TABLE 328 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 329 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 330 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 331 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 332 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 333 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 334 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 335 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 336 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 337 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 338 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.2 GERMANY
      • 12.4.2.1 High healthcare expenditure and advanced R&D facilities to drive market
    • TABLE 339 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 340 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 341 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 342 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 343 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 344 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 345 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 346 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 347 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 348 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.3 UK
      • 12.4.3.1 Rising government investments and growing focus on personalized treatment to drive market
    • TABLE 349 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 350 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 351 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 352 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 353 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 354 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 355 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 356 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 357 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 358 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.4 FRANCE
      • 12.4.4.1 Increased focus on domestic API manufacturing to boost market growth
    • TABLE 359 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 360 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 361 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 362 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 363 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 364 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 365 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 366 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 367 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 368 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.5 ITALY
      • 12.4.5.1 Increasing investment in API production to fuel market growth
    • TABLE 369 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 370 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 371 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 372 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 373 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 374 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 375 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 376 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 377 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 378 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.6 SPAIN
      • 12.4.6.1 Increase in generic drug manufacturing capacity to propel market growth
    • TABLE 379 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 380 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 381 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 382 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 383 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 384 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 385 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 386 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 387 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 388 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.7 HUNGARY
      • 12.4.7.1 Increased focus on pharmaceutical manufacturing to drive market
    • TABLE 389 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 390 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 391 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 392 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 393 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 394 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 395 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 396 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 397 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 398 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.4.8 REST OF EUROPE
    • TABLE 399 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 400 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 401 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 402 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 403 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 404 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 405 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 406 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 407 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 408 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 12.5 ASIA PACIFIC
    • 12.5.1 ASIA PACIFIC: RECESSION IMPACT
    • FIGURE 35 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET SNAPSHOT
    • TABLE 409 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 410 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 411 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 412 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 413 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 414 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 415 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 416 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 417 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 418 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 419 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.5.2 JAPAN
      • 12.5.2.1 Strong focus on drug innovation and improved R&D facilities to drive market
    • TABLE 420 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 421 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 422 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 423 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 424 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 425 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 426 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 427 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 428 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 429 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.5.3 CHINA
      • 12.5.3.1 High geriatric population and favorable government policies to support market growth
    • TABLE 430 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 431 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 432 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 433 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 434 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 435 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 436 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 437 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 438 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 439 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.5.4 INDIA
      • 12.5.4.1 Increased demand for biosimilars and favorable government healthcare policies to fuel market growth
    • TABLE 440 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 441 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 442 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 443 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 444 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 445 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 446 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 447 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 448 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 449 INDIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.5.5 SOUTH KOREA
      • 12.5.5.1 Increasing focus on quality manufacturing practices to drive market
    • TABLE 450 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 451 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 452 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 453 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 454 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 455 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 456 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 457 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 458 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 459 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.5.6 AUSTRALIA
      • 12.5.6.1 Increasing demand for innovative APIs to propel market growth
    • TABLE 460 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 461 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 462 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 463 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 464 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 465 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 466 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 467 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 468 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 469 AUSTRALIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.5.7 REST OF ASIA PACIFIC
    • TABLE 470 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 471 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 472 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 473 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 474 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 475 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 476 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 477 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 478 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 479 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 12.6 LATIN AMERICA
    • 12.6.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 480 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 481 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 482 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 (USD BILLION)
    • TABLE 483 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 484 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 485 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 486 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 487 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 488 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 489 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 490 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.6.2 BRAZIL
      • 12.6.2.1 Increased government investments in pharmaceutical R&D to drive market
    • TABLE 491 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 492 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 493 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 494 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 495 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 496 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 497 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 498 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 499 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 500 BRAZIL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.6.3 MEXICO
      • 12.6.3.1 Large investments by foreign firms and favorable regulatory policies to augment market growth
    • TABLE 501 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 502 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 503 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 504 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 505 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 506 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 507 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 508 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 509 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 510 MEXICO: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.6.4 REST OF LATIN AMERICA
    • TABLE 511 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 512 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 513 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 514 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 515 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 516 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 517 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 518 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 519 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 520 REST OF LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 12.7 MIDDLE EAST
    • 12.7.1 MIDDLE EAST: RECESSION IMPACT
    • TABLE 521 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 522 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 523 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 524 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 525 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 526 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 527 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 528 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 529 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 530 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 531 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.7.2 ISRAEL
      • 12.7.2.1 Growing financial support by government to drive market
    • TABLE 532 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 533 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 534 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 535 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 536 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 537 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 538 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 539 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 540 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 541 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.7.3 GCC COUNTRIES
    • TABLE 542 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
    • TABLE 543 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 544 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 545 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 546 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 547 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 548 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 549 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 550 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 551 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 552 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
      • 12.7.3.1 United Arab Emirates
        • 12.7.3.1.1 Growing demand for technologically advanced manufacturing processes to drive market
    • TABLE 553 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 554 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 555 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 556 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 557 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 558 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 559 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 560 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 561 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 562 UNITED ARAB EMIRATES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
      • 12.7.3.2 Saudi Arabia
        • 12.7.3.2.1 Rising healthcare expenditure and increasing number of research institutes to boost market growth
    • TABLE 563 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 564 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 565 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 566 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 567 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 568 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 569 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 570 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 571 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 572 SAUDI ARABIA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
      • 12.7.3.3 Rest of GCC countries
    • TABLE 573 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 574 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 575 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 576 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 577 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 578 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 579 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 580 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 581 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 582 REST OF GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
    • 12.7.4 REST OF MIDDLE EAST
    • TABLE 583 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 584 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 (USD BILLION)
    • TABLE 585 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 586 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 587 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 588 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 589 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 590 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 591 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 592 REST OF MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
  • 12.8 AFRICA
    • 12.8.1 GROWING DEMAND FOR PHARMACEUTICAL PRODUCTS TO PROPEL MARKET GROWTH
    • 12.8.2 AFRICA: RECESSION IMPACT
    • TABLE 593 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 594 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
    • TABLE 595 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 596 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
    • TABLE 597 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
    • TABLE 598 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
    • TABLE 599 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
    • TABLE 600 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
    • TABLE 601 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
    • TABLE 602 AFRICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 603 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: STRATEGIES ADOPTED
  • 13.3 REVENUE ANALYSIS
    • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS, 2019-2023 (USD MILLION)
  • 13.4 MARKET SHARE ANALYSIS
    • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
    • TABLE 604 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DEGREE OF COMPETITION
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • FIGURE 38 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 13.5.5.1 Overall footprint
    • FIGURE 39 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: OVERALL FOOTPRINT
      • 13.5.5.2 Type footprint
    • TABLE 605 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: TYPE FOOTPRINT
      • 13.5.5.3 Therapeutic application footprint
    • TABLE 606 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: THERAPEUTIC APPLICATION FOOTPRINT
      • 13.5.5.4 Type of drug footprint
    • TABLE 607 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: TYPE OF DRUG FOOTPRINT
      • 13.5.5.5 Regional footprint
    • TABLE 608 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONAL FOOTPRINT
  • 13.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • FIGURE 40 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
    • 13.6.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2023
    • TABLE 609 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES, 2023
    • TABLE 610 ACTIVE PHARMACEUTICAL INGREDIENTS: COMPETITIVE BENCHMARKING OF KEY START-UPS/SMES, BY TYPE AND REGION
  • 13.7 VALUATION AND FINANCIAL METRICS
    • FIGURE 41 EV/EBITDA OF KEY ACTIVE PHARMACEUTICAL INGREDIENT VENDORS
    • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY ACTIVE PHARMACEUTICAL INGREDIENT VENDORS
  • 13.8 BRAND/PRODUCT COMPARISON
    • FIGURE 43 BRAND/PRODUCT COMPARISON, BY ACTIVE PHARMACEUTICAL INGREDIENT TYPE
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 DEALS
    • TABLE 611 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DEALS, JANUARY 2021-JANUARY 2024
    • 13.9.2 EXPANSIONS
    • TABLE 612 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: EXPANSIONS, JANUARY 2021-JANUARY 2024
    • 13.9.3 OTHER DEVELOPMENTS
    • TABLE 613 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: OTHER DEVELOPMENTS, JANUARY 2021-JANUARY 2024

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
  • (Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats)**
    • 14.1.1 PFIZER INC.
    • TABLE 614 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2023)
    • TABLE 615 PFIZER INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 616 PFIZER INC.: EXPANSIONS
    • 14.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 617 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
    • FIGURE 45 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 618 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 619 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS
    • 14.1.3 GSK PLC
    • TABLE 620 GSK PLC: COMPANY OVERVIEW
    • FIGURE 46 GSK PLC: COMPANY SNAPSHOT (2023)
    • TABLE 621 GSK PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 622 GSK PLC: EXPANSIONS
    • 14.1.4 SANOFI
    • TABLE 623 SANOFI: COMPANY OVERVIEW
    • FIGURE 47 SANOFI: COMPANY SNAPSHOT (2023)
    • TABLE 624 SANOFI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 14.1.5 VIATRIS INC.
    • TABLE 625 VIATRIS INC.: COMPANY OVERVIEW
    • FIGURE 48 VIATRIS INC.: COMPANY SNAPSHOT (2023)
    • TABLE 626 VIATRIS INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 627 VIATRIS INC.: DEALS
    • TABLE 628 VIATRIS INC.: EXPANSIONS
    • 14.1.6 DIVI'S LABORATORIES LIMITED
    • TABLE 629 DIVI'S LABORATORIES LIMITED: COMPANY OVERVIEW
    • FIGURE 49 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2023)
    • TABLE 630 DIVI'S LABORATORIES LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 631 DIVI'S LABORATORIES LIMITED: DEALS
    • 14.1.7 SANDOZ GROUP AG
    • TABLE 632 SANDOZ GROUP AG: COMPANY OVERVIEW
    • FIGURE 50 SANDOZ GROUP AG: COMPANY SNAPSHOT (2023)
    • TABLE 633 SANDOZ GROUP AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 634 SANDOZ GROUP AG: EXPANSIONS
    • 14.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • TABLE 635 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
    • FIGURE 51 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2023)
    • TABLE 636 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 637 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS
    • TABLE 638 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS
    • 14.1.9 SK INC.
    • TABLE 639 SK INC.: COMPANY OVERVIEW
    • FIGURE 52 SK INC.: COMPANY SNAPSHOT (2023)
    • TABLE 640 SK INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 641 SK INC.: EXPANSIONS
    • 14.1.10 ELI LILLY AND COMPANY
    • TABLE 642 ELI LILLY AND COMPANY: COMPANY OVERVIEW
    • FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)
    • TABLE 643 ELI LILLY AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 644 ELI LILLY AND COMPANY: DEALS
    • TABLE 645 ELI LILLY AND COMPANY: EXPANSIONS
    • TABLE 646 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
    • 14.1.11 MERCK KGAA
    • TABLE 647 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 54 MERCK KGAA: COMPANY SNAPSHOT (2023)
    • TABLE 648 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 649 MERCK KGAA: EXPANSIONS
    • 14.1.12 ABBVIE INC.
    • TABLE 650 ABBVIE INC.: COMPANY OVERVIEW
    • FIGURE 55 ABBVIE INC.: COMPANY SNAPSHOT (2023)
    • TABLE 651 ABBVIE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 652 ABBVIE INC.: DEALS
    • TABLE 653 ABBVIE INC.: EXPANSIONS
    • 14.1.13 F. HOFFMANN-LA ROCHE LTD.
    • FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 654 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 14.1.14 ASTRAZENECA
    • TABLE 655 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 57 ASTRAZENECA: COMPANY SNAPSHOT (2023)
    • TABLE 656 ASTRAZENECA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 657 ASTRAZENECA: PRODUCT LAUNCHES
    • TABLE 658 ASTRAZENECA: EXPANSIONS
    • 14.1.15 DR. REDDY'S LABORATORIES LTD.
    • TABLE 659 DR. REDDY'S LABORATORIES LTD.: COMPANY OVERVIEW
    • FIGURE 58 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 660 DR. REDDY'S LABORATORIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 661 DR. REDDY'S LABORATORIES LTD.: EXPANSIONS
    • TABLE 662 DR. REDDY'S LABORATORIES LTD.: OTHER DEVELOPMENTS
    • 14.1.16 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 663 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
    • FIGURE 59 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)
    • TABLE 664 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 665 SUN PHARMACEUTICAL INDUSTRIES LTD.: DEALS
    • 14.1.17 CIPLA
    • TABLE 666 CIPLA: COMPANY OVERVIEW
    • FIGURE 60 CIPLA: COMPANY SNAPSHOT (2023)
    • TABLE 667 CIPLA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 668 CIPLA: DEALS
    • 14.1.18 AUROBINDO PHARMA
    • TABLE 669 AUROBINDO PHARMA: COMPANY OVERVIEW
    • FIGURE 61 AUROBINDO PHARMA: COMPANY SNAPSHOT (2023)
    • TABLE 670 AUROBINDO PHARMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 671 AUROBINDO PHARMA: DEALS
    • 14.1.19 EVONIK INDUSTRIES AG
    • TABLE 672 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
    • FIGURE 62 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023)
    • TABLE 673 EVONIK INDUSTRIES AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 674 EVONIK INDUSTRIES AG: DEALS
    • TABLE 675 EVONIK INDUSTRIES AG: EXPANSIONS
    • 14.1.20 HIKMA PHARMACEUTICALS PLC
    • TABLE 676 HIKMA PHARMACEUTICALS PLC: COMPANY OVERVIEW
    • FIGURE 63 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2023)
    • TABLE 677 HIKMA PHARMACEUTICALS PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • TABLE 678 HIKMA PHARMACEUTICALS PLC: DEALS
    • 14.1.21 BASF SE
    • TABLE 679 BASF SE: COMPANY OVERVIEW
    • FIGURE 64 BASF SE: COMPANY SNAPSHOT (2023)
    • TABLE 680 BASF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 14.1.22 ALEMBIC PHARMACEUTICALS LIMITED
    • TABLE 681 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
    • FIGURE 65 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023)
    • TABLE 682 ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • 14.2 OTHER PLAYERS
    • 14.2.1 ABURAIHAN PHARMACEUTICAL COMPANY
    • TABLE 683 ABURAIHAN PHARMACEUTICAL COMPANY: COMPANY OVERVIEW
    • 14.2.2 CURIA GLOBAL, INC.
    • TABLE 684 CURIA GLOBAL, INC.: COMPANY OVERVIEW
    • 14.2.3 CAMBREX CORPORATION
    • TABLE 685 CAMBREX CORPORATION: COMPANY OVERVIEW
    • 14.2.4 API PHARMA TECH
    • TABLE 686 API PHARMA TECH: COMPANY OVERVIEW
    • 14.2.5 SREEPATHI PHARMACEUTICALS LIMITED
    • TABLE 687 SREEPATHI PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
    • 14.2.6 SHILPA MEDICARE LIMITED
    • TABLE 688 SHILPA MEDICARE LIMITED: COMPANY OVERVIEW
    • 14.2.7 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.
    • TABLE 689 NANJING JIANYOU BIOCHEMICAL PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
    • 14.2.8 HOVIONE
    • TABLE 690 HOVIONE: COMPANY OVERVIEW
    • 14.2.9 CHEMCON GMBH
    • TABLE 691 CHEMCON GMBH: COMPANY OVERVIEW
    • 14.2.10 PHARCO
    • TABLE 692 PHARCO: COMPANY OVERVIEW
  • *Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strategies, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS